How Can We Help You?

Quick Info:

Find a Doctor Specialties (800) 213-3284

Go To Home PageBack

Fallopian Tube Cancer Trials

Select Clinical Trial

ORCCYD (ET743-OVC-3006): A Study Comparing the Combination of Trabectedin and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

  • Women, ages 18 years or older, with advanced-relapsed ovarian, fallopian tube, or primary peritoneal cancer. For additional criteria, call our Clinical Trials office at (910) 715-2200.

 

GOG 225: Can Diet and Physical Activity Modulate Ovarian and Primary Peritoneal Cancer Progression-Free Survival

  • Women, ages 18 years or older, with confirmed ovarian, fallopian tube, or primary peritoneal cancer. For additional criteria, call the Research Coordinator or visit the study weblink our Clinical Trials office at (910) 715-2200.

 

GOG 213: Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer

  • Women, ages 18 years or older, with confirmed recurrent ovarian, fallopian tube, or primary peritoneal cancer. For additional criteria, call the Research Coordinator or visit the study weblink our Clinical Trials office at (910) 715-2200.

 

NRG-GY005/ Ovarian/ Fallopian Tube/ Peritoneal

  • Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)

 

  • Patient population 18 Years and older with confirmed ovarian cancer, peritoneal cancer or fallopian tube cancerthat has returned after receiving chemotherapy with drugs that contain platinum (platinum-resistant) or continued to grow while being treated with platinum-based chemotherapy drugs (platinum-refractory).

 

NRG-GY004 - Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  • Female, age 18 or older, diagnosed with platinum-sensitive recurrent high-grade serous or high-grade endometrioid ovarian, primary peritoneal, or fallopian tube cancers. 
  • For additional criteria, call our Clinical Trials office at (910) 715-2200

 

Specialties
Clara McLean House
Make a Donation
News & Events